<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="article-commentary" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Int J Public Health</journal-id>
<journal-title>International Journal of Public Health</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Int J Public Health</abbrev-journal-title>
<issn pub-type="epub">1661-8564</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1607460</article-id>
<article-id pub-id-type="doi">10.3389/ijph.2024.1607460</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Public Health Archive</subject>
<subj-group>
<subject>Commentary</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Pediatric Neuromuscular Diseases and Psychosocial Wellbeing: Why We Also Need to Invest in Digital Platforms</article-title>
<alt-title alt-title-type="left-running-head">Gruebner et al.</alt-title>
<alt-title alt-title-type="right-running-head">NMDs and Digital Platform Needs</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Gruebner</surname>
<given-names>Oliver</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/846868/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Elayan</surname>
<given-names>Suzanne</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sykora</surname>
<given-names>Martin</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Wolf</surname>
<given-names>Markus</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="author-notes" rid="fn002">
<sup>&#x2021;</sup>
</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>von Rhein</surname>
<given-names>Michael</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2021;</sup>
</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Fadda</surname>
<given-names>Marta</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<xref ref-type="author-notes" rid="fn002">
<sup>&#x2021;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1194274/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Faculty of Health Sciences and Medicine</institution>, <institution>University of Lucerne</institution>, <addr-line>Lucerne</addr-line>, <country>Switzerland</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Epidemiology, Biostatistics, and Prevention Institute</institution>, <institution>University of Zurich</institution>, <addr-line>Zurich</addr-line>, <country>Switzerland</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Centre for Information Management</institution>, <institution>Loughborough University</institution>, <addr-line>Loughborough</addr-line>, <country>United Kingdom</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Department of Psychology</institution>, <institution>University of Zurich</institution>, <addr-line>Zurich</addr-line>, <country>Switzerland</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Child Development Center</institution>, <institution>University Children&#x2019;s Hospital Zurich</institution>, <institution>University of Zurich</institution>, <addr-line>Zurich</addr-line>, <country>Switzerland</country>
</aff>
<aff id="aff6">
<sup>6</sup>
<institution>Institute of Public Health</institution>, <institution>Universit&#x00E0; della Svizzera Italiana</institution>, <addr-line>Lugano</addr-line>, <country>Switzerland</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1002522/overview">Andrea Madarasova Geckova</ext-link>, University of Pavol Jozef &#x160;af&#xe1;rik, Slovakia</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Oliver Gruebner, <email>oliver.gruebner@unilu.ch</email>
</corresp>
<fn fn-type="present-address" id="fn001">
<label>
<sup>&#x2020;</sup>
</label>
<p>
<bold>Present address:</bold>
</p>
<p>Marta Fadda, Institute of Family Medicine, Universit&#x00E0; della Svizzera Italiana, Lugano, Switzerland</p>
</fn>
<fn fn-type="equal" id="fn002">
<label>
<sup>&#x2021;</sup>
</label>
<p>These authors share last authorship</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>14</day>
<month>06</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>69</volume>
<elocation-id>1607460</elocation-id>
<history>
<date date-type="received">
<day>03</day>
<month>05</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>31</day>
<month>05</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Gruebner, Elayan, Sykora, Wolf, von Rhein and Fadda.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Gruebner, Elayan, Sykora, Wolf, von Rhein and Fadda</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<kwd-group>
<kwd>accessibility</kwd>
<kwd>digital health</kwd>
<kwd>Duchenne Muscular Dystrophy</kwd>
<kwd>e-health</kwd>
<kwd>mental health</kwd>
</kwd-group>
<contract-sponsor id="cn001">Swiss School of Public Health<named-content content-type="fundref-id">10.13039/100030992</named-content>
</contract-sponsor>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Despite the ongoing digital transformation in society, certain population groups remain underserved by these advances. The promise of digital platforms, while groundbreaking in many ways, has fallen short in addressing the unique needs of young individuals and their families diagnosed with neuromuscular disorders (NMDs), including Myasthenia Gravis, Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), or several types of Muscular Dystrophies [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>].</p>
<sec id="s1-1">
<title>Support for Patients&#x2019; and Family Members&#x2019; Mental Health</title>
<p>Duchenne Muscular Dystrophy (DMD), is a hereditary disease, causing progressive loss of muscle strength leading to disability and early death [<xref ref-type="bibr" rid="B3">3</xref>]. While medical care is often the focus, &#x201c;<italic>the psychosocial challenges faced by patients and families remain in the shadows,&#x201d;</italic> says Dr. med. Hamann, Head of Child, and Adolescent Psychosomatics at Inselspital Bern. The moment of diagnosis represents an emotionally devastating turning point. <italic>&#x201c;It quickly became clear to us parents that this clinical picture would turn our entire family life upside down&#x201d;</italic> says Dominik, father of a DMD patient. Parents are confronted with the harsh reality of a significantly reduced life expectancy for their child. Yet, DMD &#x2013; like most NMDs with childhood onset - is a lifelong journey filled with evolving challenges [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>]. Patients&#x2019; progressing muscular degeneration leads to increased physical dependence, which places a heavy burden on the mental health of families [<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>]. Low-barrier access to psychologists who accompany patients and families can reduce the mental health burden. While patient organizations, such as ASRIMM, Duchenne-CH, MGR, or SMG aid in finding psychosocial support and digital repositories, such as Psyfinder are available, access to NMD-related psychological care remains elusive in Switzerland. Therefore, chat bots may become appropriate aids in finding adequate support in the future [<xref ref-type="bibr" rid="B8">8</xref>], while we must also look at patient safety [<xref ref-type="bibr" rid="B9">9</xref>].</p>
</sec>
<sec id="s1-2">
<title>Sustainment of Daily Functioning</title>
<p>The challenges posed by physical dependence on others can be overwhelming for those affected by NMDs. Depending on the degree of disability, family situation, and personal attitude of patients and families, the burden of care and related stressors can get devastating over time.</p>
<p>In Switzerland, crucial support is offered through Spitex, which provides essential ambulatory care. Families can apply for financial compensation through the IV and many Swiss cantons allow relatives to take on roles as &#x201c;caregivers&#x201d; under the Social Security Act, with guidance and support given, e.g., by AsFam. This allows families to be hired as caregivers by their disabled relatives, to receive training, and to care for their loved ones while earning an income. However, tensions may arise if patients seek independence from their parents and therefore may prefer external care. The care-related burden may become overwhelming for the parents as well. &#x201c;<italic>It quickly became clear to us that we could not care for our 100% dependent sons around the clock all week and needed a break,</italic>&#x201d; says Sacha, father of two children with DMD. &#x201c;<italic>Balancing work and family life was difficult at first, as we also have a daughter. We were therefore grateful that our children soon wanted and were able to stay overnight twice a week at a foundation facility with a training and residential home after they started school.</italic>&#x201d; In the context of physical disabilities, foundations such as MES or Rossfeld offer residential and day care groups and nursing, which may reduce such tensions among family members. Finally, not all cantons offer the same level of support for caregivers, creating disparities in access to resources.</p>
<p>Digital platforms may address these challenges through organizational tools for everyday planning, medication intake management targeted directly at patients, as well as further tools to help mitigate frequent turnover of medical personnel. Apps could provide financial and informational management tools to help caregivers navigate the complex financial landscape associated with NMD care. This empowers caregivers to make informed decisions, reduce financial stress, and ensure that their loved ones receive the care they need without compromising their own financial stability. Apps could also provide educational resources including instructional videos, and expert advice on managing care needs. Finally, apps could help bridging the gap between regions with varying levels of support for caregivers. They could provide information on available services, support networks, and resources specific to each canton as well as highly specific expertise outside one&#x2019;s local region.</p>
</sec>
<sec id="s1-3">
<title>Social Inclusion</title>
<p>In the context of DMD and other NMDs, the challenges extend to low levels of social integration, including childcare, kindergarten, school, and work environments. Within these domains, there&#x2019;s a risk that children may find themselves excluded from social activities, particularly when they struggle to keep up with their peers. This lack of alignment can have detrimental effects on their social development, self-esteem, or feelings of exclusion and isolation.</p>
<p>When a special education status ISR is in place, the presence of personal assistance from kindergarten level onwards can be a game-changer in managing daily activities, bridging the gap between educational settings and routine consultations with healthcare providers. Patient organizations also offer much-needed counseling, educational training, and information sessions for schoolchildren to create inclusive settings for teachers and students. Digital peer support platforms can bring families and affected persons together to reduce stigmatization and enhance inclusion right from the early stages of the disease.</p>
</sec>
<sec id="s1-4">
<title>Accessibility and Mobility</title>
<p>The built environment, encompassing public and private buildings, fails to meet the diverse social and healthcare needs of individuals affected by NMDs. Even some healthcare facilities themselves are inaccessible. <italic>&#x201c;It never ceases to amaze me that during the regular examinations for our sons</italic> [&#x2026;] <italic>an escort must always be present, because in the hospital, for example, there is no equipment whatsoever for the back radiography, such as a hoisting lift, to examine people with muscle disease,&#x201d;</italic> says Sacha. Yet, the hurdles are not solely structural. Communication barriers come into play as well, with some individuals affected by disabilities facing challenges in verbally expressing their needs due to speech difficulties linked to their condition, fear of stigma, or shame to seek assistance.</p>
<p>In Switzerland, public transport must be fully accessible [<xref ref-type="bibr" rid="B10">10</xref>]. However, the reality often does not meet this standard. <italic>&#x201c;When our sons come home on the weekends, we have to plan it very carefully in advance with the SBB train company.&#x201d;</italic> continues Sacha, <italic>&#x201c;Ramps have to be organized to board the train, and an external escort service has to bring them onto the train in Zurich, so that we can then pick them up again at our station.&#x201d;</italic> This compounds the already intricate web of challenges patients with NMD and their families face.</p>
<p>Opportunities emerge from Smart Cities and Internet of Things (IoT). IoT applications may allow for a more equitable and inclusive urban design and transit options facilitating interaction with the environment <italic>via</italic> sensors and digital devices. Traffic lights may be equipped with an interface or programmed so that they become aware of people with reduced mobility to give them more time to cross the streets, while adequately slowing down motorized individual traffic. Furthermore, elevators can be equipped with sensors so that disabled individuals can use them with their smartphones without having to press buttons. Also, navigation tools should contain options for accessibility routing allowing, e.g., wheelchair users to independently navigate the city or use public transport independently.</p>
</sec>
</sec>
<sec sec-type="conclusion" id="s2">
<title>Conclusion</title>
<p>We must collectively acknowledge the untapped potential of digital platforms in supporting patients and families affected by NMDs. To realize this potential, a transdisciplinary and comprehensive approach is needed to encompass the technical aspects alongside the ethical, legal, social, and practical dimensions. The task at hand extends beyond merely bridging the digital divide; it is about ensuring that both digital and physical worlds become genuinely inclusive, reliable, trustworthy, and developed with a steadfast commitment to equity at their core. We believe that such improvements could also serve as an example for very similar challenges regarding children with other disabling neuropediatric disorders and their families.</p>
</sec>
</body>
<back>
<sec id="s3">
<title>Author Contributions</title>
<p>Conceptualisation: OG and MF. Writing: MF and OG. Editing: OG, SE, MS, MW, MvR, and MF. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec sec-type="funding-information" id="s4">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. Swiss School of Public Health (SSPH&#x2b;) grant to OG.</p>
</sec>
<sec sec-type="COI-statement" id="s5">
<title>Conflict of Interest</title>
<p>OG is president of Duchenne-CH, a patient organization that supports patients and families affected by DMD in Switzerland.</p>
<p>The remaining authors declare that they do not have any conflicts of interest.</p>
</sec>
<ack>
<p>We thank Dominik and Sacha who accepted to share their stories with us and to include some portions of their accounts in this article. Original names have been retained with permission. We would also like to thank Christoph Hamann (Inselspital Bern) for his help. This work is based on a workshop and a conference on the topic [<xref ref-type="bibr" rid="B1">1</xref>]. We thank all participants for their invaluable contributions: Anna Hug (University of Zurich, Department of Geography), Afua van Haasteren and Emiliano Albanese (Universit&#xe0; della Svizzera italiana, Institute of Public Health), Georg M. Stettner (University of Zurich, University Children&#x2019;s Hospital Zurich, Neuromuscular Center Zurich and Department of Pediatric Neurology), Veronika Waldboth (Zurich University of Applied Sciences, Institute of Nursing), Sandra Messmer-Khosla (Schweizerische Muskelgesellschaft), Cornelia Enzmann (University Children&#x2019;s Hospital Basel, Department of Neuropediatrics, Neuromuscular Center), Dominique Baumann (University of Bern, Institute of Social and Preventive Medicine, Swiss Registry for Neuromuscular Disorders, Swiss-Reg-NMD), Viktor von Wyl (University of Zurich, Epidemiology, Biostatistics, and Prevention Institute). Finally, we thank the Swiss School of Public Health (SSPH&#x2b;) for financial support of the RISE (Raising awareness for mental health in patients and families affected by paediatric neuromuscular diagnosis leading to severe disability) project.</p>
</ack>
<sec id="s6">
<title>Abbreviations</title>
<p>ALS: Amyotrophic Lateral Sclerosis; ASFAM: Assistenz f&#x00FC;r Familien mit pflegenden Angeh&#x00F6;rigen, <ext-link ext-link-type="uri" xlink:href="http://www.asfam.ch/">www.asfam.ch</ext-link>; ASRIMM: Association Suisse Romande Intervenant contre les Maladies neuroMusculaires, <ext-link ext-link-type="uri" xlink:href="https://www.asrimm.ch/">https://www.asrimm.ch</ext-link>; DMD: Duchenne Muscular Dystrophy; Duchenne-CH: Duchenne Schweiz, <ext-link ext-link-type="uri" xlink:href="https://www.duchenne-schweiz.ch/">https://www.duchenne-schweiz.ch</ext-link>; ISR: Integrierte Sonderschulung in der Verantwortung der Regelschule. For example, ISR regulations of Canton Zurich are available here: <ext-link ext-link-type="uri" xlink:href="https://www.zh.ch/de/bildung/informationen-fuer-schulen/informationen-volksschule/volksschule-schulinfo-besonderer-bildungsbedarf/schulinfo-sonderschulung.html">https://www.zh.ch/de/bildung/informationen-fuer-schulen/informationen-volksschule/volksschule-schulinfo-besonderer-bildungsbedarf/schulinfo-sonderschulung.html</ext-link>; IV: Invalidenversicherung, <ext-link ext-link-type="uri" xlink:href="https://www.ahv-iv.ch/de/Sozialversicherungen/Invalidenversicherung-IV/Hilflosenentsch&#xe4;digung">https://www.ahv-iv.ch/de/Sozialversicherungen/Invalidenversicherung-IV/Hilflosenentsch&#xe4;digung</ext-link>; NMD: Neuromuscular Disorder; MES: Mathilde Escher Stiftung: <ext-link ext-link-type="uri" xlink:href="https://www.mathilde-escher.ch/">https://www.mathilde-escher.ch</ext-link>; MGR: Associazione Malattie Genetiche Rare Svizzera italiana, <ext-link ext-link-type="uri" xlink:href="https://www.malattiegeneticherare.ch/">https://www.malattiegeneticherare.ch</ext-link>; Rossfeld: Stiftung Rossfeld, <ext-link ext-link-type="uri" xlink:href="https://www.rossfeld.ch/">https://www.rossfeld.ch</ext-link>; SBB: Schweizerische Bundesbahnen, for example, the contact center handicap: <ext-link ext-link-type="uri" xlink:href="https://www.sbb.ch/en/timetable/travel-advice/passengers-with-reduced-mobility/sbb-call-center-handicap.html">https://www.sbb.ch/en/timetable/travel-advice/passengers-with-reduced-mobility/sbb-call-center-handicap.html</ext-link>; SMA: Spinal Muscular Atrophy; SMG: Schweizerische Muskelgesellschaft, <ext-link ext-link-type="uri" xlink:href="https://www.muskelgesellschaft.ch/">https://www.muskelgesellschaft.ch</ext-link>; Spitex: Swiss home care nursing service, Umbrella organization: <ext-link ext-link-type="uri" xlink:href="https://www.spitex.ch/">https://www.spitex.ch</ext-link>; SSPH&#x2b;: Swiss School of Public Health, <ext-link ext-link-type="uri" xlink:href="https://ssphplus.ch/">https://ssphplus.ch</ext-link>; Psyfinder: <ext-link ext-link-type="uri" xlink:href="https://www.psychologie.ch/psychologensuche">https://www.psychologie.ch/psychologensuche</ext-link>.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gruebner</surname>
<given-names>O</given-names>
</name>
<name>
<surname>van Haasteren</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hug</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Elayan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sykora</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Albanese</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group> <article-title>Mental Health Challenges and Digital Platform Opportunities in Patients and Families Affected by Pediatric Neuromuscular Diseases - Experiences from Switzerland</article-title>. <source>Digit Health</source> (<year>2023</year>) <volume>9</volume>:<fpage>20552076231213700</fpage>. <pub-id pub-id-type="doi">10.1177/20552076231213700</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gruebner</surname>
<given-names>O</given-names>
</name>
<name>
<surname>van Haasteren</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hug</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Elayan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sykora</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Albanese</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group> <article-title>Digital Platform Uses for Help and Support Seeking of Parents with Children Affected by Disabilities: Scoping Review</article-title>. <source>J Med Internet Res</source> (<year>2022</year>) <volume>24</volume>(<issue>12</issue>):<fpage>e37972</fpage>. <pub-id pub-id-type="doi">10.2196/37972</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rind</surname>
<given-names>DM</given-names>
</name>
</person-group>. <article-title>The FDA and Gene Therapy for Duchenne Muscular Dystrophy</article-title>. <source>JAMA</source> (<year>2024</year>) <volume>331</volume>:<fpage>1705</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2024.5613</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colvin</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Poysky</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kinnett</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Damiani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gibbons</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hoskin</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Psychosocial Management of the Patient with Duchenne Muscular Dystrophy</article-title>. <source>Pediatrics</source> (<year>2018</year>) <volume>142</volume>(<issue>Suppl. ment_2</issue>):<fpage>S99</fpage>&#x2013;<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2018-0333L</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fee</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Hinton</surname>
<given-names>VJ</given-names>
</name>
</person-group>. <article-title>Resilience in Children Diagnosed with a Chronic Neuromuscular Disorder</article-title>. <source>J Dev Behav Pediatr</source> (<year>2011</year>) <volume>32</volume>(<issue>9</issue>):<fpage>644</fpage>&#x2013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1097/DBP.0b013e318235d614</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Henzi</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Baumann</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Erni</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>L&#xf6;tscher</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tscherter</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>Effects of the COVID-19 Pandemic on Access to Education and Social Participation in Children and Adolescents with Duchenne Muscular Dystrophy in Switzerland</article-title>. <source>Neuropediatrics</source> (<year>2023</year>) <volume>54</volume>:<fpage>287</fpage>&#x2013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1055/s-0043-1764434</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Waldboth</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Patch</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mahrer-Imhof</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Metcalfe</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>The Family Transition Experience when Living with Childhood Neuromuscular Disease: A Grounded Theory Study</article-title>. <source>J Adv Nurs</source> (<year>2021</year>) <volume>77</volume>(<issue>4</issue>):<fpage>1921</fpage>&#x2013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1111/jan.14754</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ayers</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Poliak</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dredze</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Leas</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Kelley</surname>
<given-names>JB</given-names>
</name>
<etal/>
</person-group> <article-title>Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media Forum</article-title>. <source>JAMA Intern Med</source> (<year>2023</year>) <volume>183</volume>(<issue>6</issue>):<fpage>589</fpage>&#x2013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1001/jamainternmed.2023.1838</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ratwani</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Bates</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Classen</surname>
<given-names>DC</given-names>
</name>
</person-group>. <article-title>Patient Safety and Artificial Intelligence in Clinical Care</article-title>. <source>JAMA Health Forum</source> (<year>2024</year>) <volume>5</volume>(<issue>2</issue>):<fpage>e235514</fpage>. <pub-id pub-id-type="doi">10.1001/jamahealthforum.2023.5514</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10.</label>
<citation citation-type="web">
<collab>Federal Office of Transport (FOT)</collab>. <article-title>Legal Regulations. Bern</article-title> (<year>2024</year>). <comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://www.bav.admin.ch/bav/en/home/general-topics/accessible-public-transport/legal-regulations.html">https://www.bav.admin.ch/bav/en/home/general-topics/accessible-public-transport/legal-regulations.html</ext-link> (Accessed May 30, 2024)</comment>.</citation>
</ref>
</ref-list>
</back>
</article>